The efficacy of tazarotene 0.1% gel in a 30-year-old woman with type I lamellar ichthyosis is reported. The drug was applied to 15% of the total body surface area as follows: once daily for 2 weeks, three times a week for further 2 weeks, followed by a once weekly maintenance application. During the first week of treatment there was partial improvement obtained and in the next 14 days further reduction of scaling within the tazarotene-treated areas was observed. After 4 months of maintenance application, there was a marked overall improvement in the treated areas. Side-effects consisted only of mild pruritus, slight burning and irritation. In essence, the therapeutic benefit obtained was comparable with that of systemic retinoids but without the adverse systemic side-effects. As noted in other reports, tazarotene 0.1% gel seems to be a valuable and safe therapeutic option for this severe genodermatosis.
Marulli, G., Campione, E., Chimenti, M.s., Terrinoni, A., Melino, G., Bianchi, L. (2003). Type I lamellar ichthyosis improved by tazarotene 0.1% gel. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 28(4), 391-393 [10.1046/j.1365-2230.2003.01318.x].
Type I lamellar ichthyosis improved by tazarotene 0.1% gel
CAMPIONE, ELENA;CHIMENTI, MARIA SOLE;Terrinoni, A;MELINO, GENNARO;BIANCHI, LUCA
2003-01-01
Abstract
The efficacy of tazarotene 0.1% gel in a 30-year-old woman with type I lamellar ichthyosis is reported. The drug was applied to 15% of the total body surface area as follows: once daily for 2 weeks, three times a week for further 2 weeks, followed by a once weekly maintenance application. During the first week of treatment there was partial improvement obtained and in the next 14 days further reduction of scaling within the tazarotene-treated areas was observed. After 4 months of maintenance application, there was a marked overall improvement in the treated areas. Side-effects consisted only of mild pruritus, slight burning and irritation. In essence, the therapeutic benefit obtained was comparable with that of systemic retinoids but without the adverse systemic side-effects. As noted in other reports, tazarotene 0.1% gel seems to be a valuable and safe therapeutic option for this severe genodermatosis.File | Dimensione | Formato | |
---|---|---|---|
Type I lamellar ichthyosis improved by tazarotene 0.1% gel, Clinical and Experimental Dermatology, 2003, 28, 391–393.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
75.72 kB
Formato
Adobe PDF
|
75.72 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.